All News
Filter News
Found 4,202 articles
-
Merck is looking to expand its offerings in the human papillomavirus space with a new vaccine and to study a single-shot variant of Gardasil 9, both of which will start trials toward the end of 2024.
-
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
3/12/2024
BioXcel Therapeutics, Inc. provided an update on its late-stage TRANQUILITY and SERENITY clinical programs.
-
KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported
3/12/2024
Kineta, Inc. announced an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 as monotherapy and in combination with Merck’s anti-PD therapy, KEYTRUDA® in patients with advanced solid tumors.
-
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
3/12/2024
IDEAYA Biosciences, Inc. announced that it has entered into a clinical trial collaboration and supply agreement with Merck to evaluate IDE161, the company's investigational, potential first-in-class, small molecule poly glycohydrolase, or PARG, inhibitor, in combination with KEYTRUDA® Merck's anti-PD-1 therapy, in patients with microsatellite instability-, or MSI-, high and microsatellite stable, or MSS, endometrial cancer, in a Phase 1 clinical trial.
-
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
3/12/2024
Genprex, Inc. announced that the Korean Patent Office has issued a Notice of Patent Grant for a broad patent that covers the use of Genprex's lead drug candidate, Reqorsa® Immunogene Therapy, in combination with anti-PD-1 and PD-L1 antibodies through 2037.
-
TiumBio to Initiate Phase 2 Trial of TU2218 for Cancer
3/11/2024
TiumBio Co., Ltd. announced that it has submitted Investigational New Drug (IND) application to the Korean Ministry of Food and Drug Safe (MFDS) for a Phase 2a study of TU2218, an oral immuno-oncology drug, in late February, 2024 and that preclinical results of TU2218 will be presented at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting.
-
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
3/11/2024
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided recent business highlights and reported financial results for the fourth quarter and full year ended December 31, 2023.
-
The approval, which Bristol Myers Squibb reported on Thursday, positions the company to compete with Astellas and Pfizer’s Padcev.
-
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
3/7/2024
ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
-
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
3/6/2024
iTeos Therapeutics, Inc. announced the appointment of Jill DeSimone to its Board of Directors, effective March 7, 2024, where she will serve on the Company’s audit committee.
-
Crescendo Biologics to present at the 2024 AACR Annual Meeting
3/6/2024
Crescendo Biologics Ltd, a clinical stage, immuno-oncology company developing novel, targeted T cell enhancing therapeutics, will be presenting two poster presentations at the 2024 American Association for Cancer Research Annual Meeting, taking place in San Diego, California from 5-10 April 2024.
-
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
3/6/2024
Werewolf Therapeutics, Inc. today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 9:20 AM ET on March 13, 2024, at the Leerink Partners Global Biopharma Conference, taking place March 11-13, 2024, in Miami, Florida.
-
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
3/6/2024
Genprex, Inc. today announced that its research collaborators will present at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024 in San Diego, California.
-
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
3/6/2024
IO Biotech (Nasdaq: IOBT) today announced that an abstract has been accepted for presentation at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA.
-
CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China
3/5/2024
CASI Pharmaceuticals, Inc. and BioInvent International AB announced preliminary encouraging efficacy data for BI-1206 in combination with rituximab in patients with relapsed/refractory indolent Non-Hodgkin's Lymphoma in the ongoing development program in China.
-
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)Milestone triggered by clinical progress in Phase 1 study, initiated in Q4 2023
3/5/2024
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, announced that Pfizer has achieved a clinical development milestone for PF-08046052, prompting the first milestone payment of $7 Million to LAVA.
-
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
3/5/2024
IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today reported financial results for the fourth quarter and year-ended December 31, 2023.
-
Mallinckrodt Announces Appointment of Paul O'Neill as Executive Vice President, Quality & Operations, Specialty Brands
3/4/2024
Mallinckrodt plc, a global specialty pharmaceutical company, announced that Paul O'Neill has been appointed Executive Vice President, Quality & Operations, Specialty Brands, effective immediately.
-
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
2/29/2024
Cue Biopharma, Inc. announced today that the company’s lead clinical asset, CUE-101, will be featured in a presentation at the 2024 Multi-disciplinary Head and Neck Cancers Symposium given by Alexander Dimitrios Colevas, M.D., a principal investigator at Stanford University participating in the CUE-101 clinical trial.
-
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
2/29/2024
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.